Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

This study tests a combination of five drugs — venetoclax, azacitidine, chidamide, vindesine, and dexamethasone — in newly diagnosed patients with a rare and aggressive type of blood cancer called ETP-ALL (early T-cell precursor acute lymphoblastic leukemia). This leukemia is particularly hard to treat with standard chemotherapy. **You may be eligible if...** - You are between 14 and 65 years old - You have been newly diagnosed with ETP-ALL or a similar type, confirmed by specialized lab testing (flow cytometry and/or genetic mutation testing) - You have not received prior induction chemotherapy - Your physical performance is adequate (ECOG 0–2) - You have an expected survival of more than 6 months **You may NOT be eligible if...** - You are pregnant - You have significant heart, liver, or kidney problems - You have an active serious infection Talk to your doctor to see if this trial is right for you.